Hostname: page-component-745bb68f8f-5r2nc Total loading time: 0 Render date: 2025-02-06T17:48:28.139Z Has data issue: false hasContentIssue false

Role of limited parotidectomy in management of pleomorphic adenoma

Published online by Cambridge University Press:  01 August 2007

J T Johnson
Affiliation:
Department of Otolaryngology, School of Medicine, University of Pittsburgh, Pennsylvania, USA
A Ferlito*
Affiliation:
ENT Clinic, Department of Surgical Sciences, University of Udine, Italy
J J Fagan
Affiliation:
Division of Otolaryngology, Faculty of Health Sciences, University of Cape Town, South Africa
P J Bradley
Affiliation:
Department of Otorhinolaryngology-Head and Neck Surgery, Queen's Medical Centre, Nottingham, UK
A Rinaldo
Affiliation:
ENT Clinic, Department of Surgical Sciences, University of Udine, Italy
*
Address for correspondence: Professor Alfio Ferlito, Director of the Department of Surgical Sciences, Professor and Chairman of the ENT Clinic, Policlinico Universitario, University of Udine, Piazzale S Maria della Misericordia, I-33100 Udine, Italy. Fax: +39 0432 559339 E-mail: a.ferlito@uniud.it
Rights & Permissions [Opens in a new window]

Abstract

There is continued controversy over the extent of parotidectomy required for removal of a benign pleomorphic adenoma from the parotid gland. Currently, consensus exists that the integrity of the facial nerve must be preserved when the tumour is totally removed.

As a result of experience gained in the first half of the twentieth century, it was recommended that superficial parotidectomy with facial nerve dissection should be the minimal biopsy for pleomorphic adenoma. Since that time, however, research has indicated that partial parotidectomy or extracapsular dissection of benign pleomorphic adenoma can be accomplished with preservation of the facial nerve without an increase in tumour recurrence. Partial parotidectomy or extracapsular dissection results in impaired cosmetic results and a lower incidence of Frey's syndrome, and thus may be the preferred approach when undertaken by experienced surgeons.

Type
Review Articles
Copyright
Copyright © JLO (1984) Limited 2007

Pleomorphic adenoma is the most commonly encountered tumour of the parotid gland and represents approximately 80 per cent of all benign neoplasms.Reference Spiro1 Complete excision results in cure in the overwhelming majority of patients. Untreated, a small but important cohort of tumours will undergo malignant transformation.Reference Bradley2 Incomplete removal is associated with recurrence. These recurrences are often multifocal and may be associated with malignant transformation (with a metastasising form of pleomorphic adenoma being associated with a fatal outcome in 20 per cent).Reference Bradley2, Reference Nouraei, Ferguson, Clarke, Sandison, Sandhu and Michaels3 Surgery for recurrent pleomorphic adenoma is associated with a greater risk of injury to the facial nerve.Reference Bradley4

In the first half of the twentieth century, surgical reports described tumour enucleation and other forms of subtotal removal.Reference Benedict and Meigs5Reference Rawson, Howard, Royster and Horn7 These approaches appear to have been motivated by an effort to reduce risk to the facial nerve, and also a lack of understanding of the biology of these mixed tumours. Recurrence was observed in 23–31 per cent of patients treated in this way.

Benedict and Meigs,Reference Benedict and Meigs5 of the Massachusetts General Hospital, reported their surgical experience in 40 patients with mixed tumours of the parotid glands. All patients were followed for more than five years. Recurrences were observed in 12 patients (30 per cent).

McFarland,Reference McFarland8 from the University of Pennsylvania, observed 69 recurrences (23 per cent) in 300 patients treated for benign pleomorphic adenoma. Joseph McFarland is credited with making the observation that recurrent pleomorphic adenoma may occur many years after initial therapy.

Rawson et al.,Reference Rawson, Howard, Royster and Horn7 also from the University of Pennsylvania, followed 45 patients for 10 years or more. Recurrence was observed in 14 patients (31 per cent).

However, in the latter half of the twentieth century, the minimum recommended approach to parotid neoplasia changed. Patey and ThackrayReference Patey and Thackray9 reported in the British Journal of Surgery that the standardisation of parotidectomy techniques had revolutionised surgery of the parotid glands. They cautioned against biopsy, indicating that a small sample from a heterogeneous tumour may be misleading, and they concluded with the recommendation that the standard operation for parotid tumours lateral to the facial nerve should be superficial conservative parotidectomy. These authors were of the opinion that the most important factors responsible for the recurrence of primary mixed tumours were incomplete excision and implantation. They rejected multiplicity of tumour foci as a significant factor.

Complete superficial parotidectomy with facial nerve dissection affords the surgeon an opportunity to maximally expose the facial nerve, the goal of which is, of course, to protect the nerve. It also gives the surgeon an opportunity to completely remove the pleomorphic adenoma together with a margin of normal gland.

The justification for superficial parotidectomy with facial nerve dissection was the prevailing surgical concept that the best means of protecting the nerve was complete dissection and exposure of the nerve. It was also based on the observation that some pleomorphic adenomas appeared not to be entirely encapsulated. Therefore, taking a margin of apparently normal tissue seemed prudent and perhaps necessary.

Complete facial nerve dissection with total removal of the lateral aspect of the gland is effective in curing most patients with pleomorphic adenoma. Unfortunately, some patients do experience temporary or permanent damage to the facial nerve. Most patients have a significant soft tissue defect, and Frey's syndrome is a common sequela.

Donovan and ConleyReference Donovan and Conley10 challenged the concept of complete superficial parotidectomy for pleomorphic adenoma. In 1984, they published a careful examination of a large series of patients successfully treated for pleomorphic adenoma. In 60 per cent of patients, there had been no margin of normal tissue on the capsule of the tumour because the margin was abutting a branch of the facial nerve itself. In every case, the nerve was preserved. Recurrence was not observed. These authors challenged the necessity of taking a wide margin of normal parotid tissue when removing pleomorphic adenomas.

European surgeons have long advocated extracapsular dissection and removal of select pleomorphic adenomas without dissection of the facial nerve and without removing a rim of tissue as a margin. Dallera et al. Reference Dallera, Marchetti and Campobassi11 presented the results of local capsular dissection in 71 patients with pleomorphic adenoma of the parotid gland. Recurrence occurred in four patients (5.6 per cent): two had been treated for a tumour of the deep lobe, and two for a tumour of the superficial lobe. The authors recommended careful follow up, with re-examination every six months in order to diagnose recurrences at an early stage.

McGurk et al. Reference McGurk, Renehan, Gleave and Hancock12 reported a series of patients treated between 1947 and 1992 at the Christie Hospital, Manchester. ‘Extracapsular dissection’ was performed in 380 patients and standard superficial parotidectomies in 95 patients. Recurrence was observed in 2 per cent of each group (median follow up was 12.5 years). These authors emphasised that extracapsular dissection did not equate to enucleation. It requires careful dissection of the tumour outside the capsule, and does not require prior identification of the facial nerve. McGurk et al. reported cure rates similar to those for superficial parotidectomy. The incidence of injury to the facial nerve was similar to or less than that observed following superficial parotidectomy. The incidence of cosmetic defects and subsequent Frey's syndrome were remarkably improved. In particular, post-operative Frey's syndrome was recorded in 38 per cent of patients following superficial parotidectomies and in 5 per cent following extracapsular dissection.

HancockReference Hancock13 indicated an ‘elective local extracapsular dissection’ as an alternative to superficial parotidectomy in selected cases of benign parotid tumours, including pleomorphic adenoma. This author concluded that local dissection gave similar results to conventional nerve dissection, with less morbidity, and confirmed that tumour recurrence cannot be ascribed to any properties of the tumour but instead lies in the hands of the surgeon, depending upon the care with which the tumour is removed.

Witt's study findingsReference Witt14 suggested that cases of small parotid pleomorphic adenoma treated by less complete parotidectomy (enucleation excluded), and hence involving less facial nerve dissection, are not at higher risk of recurrence. McGurk et al. Reference McGurk, Thomas and Renehan15 advocated ‘extracapsular dissection’ for clinically benign parotid lumps and suggested that this was a viable alternative to superficial parotidectomy for the majority of parotid tumours, being associated with reduced morbidity without oncological compromise. Patient selection criteria for such a limited procedure have not yet been defined. However, the procedure should be advocated only when undertaken by ‘experienced surgeons’.Reference Iizuka and Ishikawa16 Stennert et al. Reference Stennert, Guntinas-Lichius, Klussmann and Arnold17 reviewed the histopathology of 100 unselected cases, commenting on the tumour stroma, capsule integrity and tumour penetration, and concluded that, depending on the location of the tumour, a lateral or total parotidectomy is the recommended treatment of choice.

Wen et al. Reference Wen, Chen and Wang18 offered pathology-based arguments for partial parotidectomy for pleomorphic adenoma, and concluded that it was a safe method and could remove tumour completely.

O'Brien,Reference O'Brien19 of the Sydney Head and Neck Cancer Institute, argued that complete superficial parotidectomy is unnecessary for treatment of benign, localised parotid tumours. This author supported the role of limited superficial parotidectomy in the management of benign parotid tumours, and found that the procedure was associated with very low morbidity and recurrence rates. Frey's syndrome was not reported in this study, which included 254 cases of pleomorphic adenoma. The surgeons of the Latvian Oncological CenterReference Kornevs, Tars, Bigestans and Lauskis20 have also supported limited superficial parotidectomy.

When dealing with pleomorphic adenoma deep to the facial nerve, the lateral parenchyma of the parotid is dissected off the nerve to facilitate mobilisation of the nerve and delivery of tumour from beneath the nerve. Subsequently, when the lateral lobe of the parotid gland is returned to its anatomical position and the wound is closed, recurrence is almost never observed.

Conclusion

Complete removal of pleomorphic adenoma with preservation of an intact facial nerve is, of necessity, the goal when treating every patient. This goal can clearly be better accomplished with procedures associated with less morbidity than complete superficial parotidectomy. The use of superficial parotidectomy, classical or partial, has stood the test of time and should be within the acceptable expertise of the modern, competent surgeon. If extracapsular dissection is to be more widely accepted, then the onus is on training future surgeons in the precise technique required to safely remove these tumours without nerve injury or tumour spillage.Reference Bradley21

References

1 Spiro, RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 1986;8:177–84CrossRefGoogle ScholarPubMed
2 Bradley, PJ. ‘Metastasizing pleomorphic salivary adenoma’ should now be considered a low-grade malignancy with a lethal potential. Curr Opin Otolaryngol Head Neck Surg 2005;13:123–6CrossRefGoogle ScholarPubMed
3 Nouraei, SAR, Ferguson, MS, Clarke, PM, Sandison, A, Sandhu, GS, Michaels, L et al. Metastasizing pleomorphic salivary adenoma. Arch Otolaryngol Head Neck Surg 2006;132:788–93CrossRefGoogle ScholarPubMed
4 Bradley, PJ. Recurrent salivary gland pleomorphic adenoma: etiology, management, and results. Curr Opin Otolaryngol Head Neck Surg 2001;9:100–8CrossRefGoogle Scholar
5 Benedict, EB, Meigs, JV. Tumors of the parotid gland: A study of two hundred and twenty-five cases with complete end-results in eighty cases. Surg Gynecol Obstet 1930;51:626–47Google Scholar
6 McFarland, J. Three hundred mixed tumors of the salivary glands, of which sixty-nine recurred. Surg Gynecol Obstet 1936;63:457–68Google Scholar
7 Rawson, AJ, Howard, JM, Royster, HP, Horn, RC Jr. Tumors of the salivary glands: a clinicopathological study of 160 cases. Cancer 1950;3:445–583.0.CO;2-U>CrossRefGoogle ScholarPubMed
8 McFarland, J. Mysterious mixed tumors of salivary glands. Surg Gynecol Obstet 1943;76:2334Google Scholar
9 Patey, DH, Thackray, AC. The treatment of parotid tumours in the light of a pathological study of parotidectomy material. Br J Surg 1958;45:477–87CrossRefGoogle ScholarPubMed
10 Donovan, DT, Conley, JJ. Capsular significance in parotid tumor surgery: reality and myths of lateral lobectomy. Laryngoscope 1984;94:324–9CrossRefGoogle ScholarPubMed
11 Dallera, P, Marchetti, C, Campobassi, A. Local capsular dissection of parotid pleomorphic adenomas. Int J Oral Maxillofac Surg 1993;22:154–7CrossRefGoogle ScholarPubMed
12 McGurk, M, Renehan, A, Gleave, EN, Hancock, BD. Clinical significance of the tumour capsule in the treatment of parotid pleomorphic adenomas. Br J Surg 1996;83:1747–9CrossRefGoogle ScholarPubMed
13 Hancock, BD. Clinically benign parotid tumours: local dissection as an alternative to superficial parotidectomy in selected cases. Ann R Coll Surg Engl 1999;81:299301Google ScholarPubMed
14 Witt, RL. The significance of the margin in parotid surgery for pleomorphic adenoma. Laryngoscope 2002;112:2141–54CrossRefGoogle ScholarPubMed
15 McGurk, M, Thomas, BL, Renehan, AG. Extracapsular dissection for clinically benign parotid lumps: reduced morbidity without oncological compromise. Br J Cancer 2003;89:1610–13CrossRefGoogle ScholarPubMed
16 Iizuka, K, Ishikawa, K. Surgical techniques for benign parotid tumors: segmental resection vs extracapsular lumpectomy. Acta Otolaryngol Suppl 1998;537:7581Google ScholarPubMed
17 Stennert, E, Guntinas-Lichius, O, Klussmann, JP, Arnold, G. Histopathology of pleomorphic adenoma in parotid gland: a prospective unselected series of 100 cases. Laryngoscope 2001;111:2195–200CrossRefGoogle ScholarPubMed
18 Wen, Y, Chen, R, Wang, C. The pathologic basis of partial parotidectomy in parotid pleomorphic adenoma treatment [in Chinese]. Hua Xi Kou Qiang Yi Xue Za Zhi 2003;21:359–60Google ScholarPubMed
19 O'Brien, CJ. Current management of benign parotid tumors – the role of limited superficial parotidectomy. Head Neck 2003;25:946–52CrossRefGoogle ScholarPubMed
20 Kornevs, E, Tars, J, Bigestans, A, Lauskis, G. Treatment of parotid gland tumors in Latvian Oncological Center. Stomatologija 2005;7:110–14Google ScholarPubMed
21 Bradley, PJ. Pleomorphic salivary adenoma of the parotid gland: which operation to perform? Curr Opin Otolaryngol Head Neck Surg 2004;12:6970CrossRefGoogle ScholarPubMed